multiple

TCL Secures Multiple Honors at IFA 2025 with Cutting-edge Smart-Living Solutions

BERLIN, Sept. 10, 2025 /PRNewswire/ -- TCL, a global leader in consumer electronics and the world's No. 1 Mini LED…

3 months ago

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX…

3 months ago

Hunan TV Show Singer 2025 Draws Performers from Multiple Countries

CHANGSHA, China, Aug. 4, 2025 /PRNewswire/ -- Hunan TV's Mango TV program Singer 2025 is redefining global cultural exchange, using…

4 months ago

China Southern Power Grid Showcases Multiple AI Achievements at 2025 World Artificial Intelligence Conference

SHANGHAI, July 30, 2025 /PRNewswire/ -- From July 26 to 28, the 2025 World Artificial Intelligence Conference (WAIC) convened in Shanghai…

4 months ago

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE

Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured…

4 months ago

Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase…

4 months ago

Chambers and Partners Research Yields Multiple Global Honors for J.S. Held Experts

JERICHO, N.Y., June 26, 2025 /PRNewswire/ -- Global consulting firm J.S. Held is honored to be recognized by Chambers and…

5 months ago

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical…

6 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

6 months ago

Persistent Achieves Top Rankings for the Second Year in a Row in Extel’s Asia Executive Team Survey

Recognized under multiple categories, including Best CEO, Company Board of Directors, Overall ESG, Best Investor Relations Program, and Best Investor…

6 months ago